MODERN METHODS FOR THE TREATMENT OF SYSTEMIC SCLEROSIS: AN EVIDENCE-BASED REVIEW OF CONTEMPORARY THERAPEUTIC STRATEGIES

Abstract

Systemic sclerosis is a severe multisystem autoimmune connective tissue disease characterized by immune dysregulation, vasculopathy, and progressive fibrosis of the skin and internal organs, and it remains one of the rheumatic diseases with the highest burden of morbidity and mortality. In recent years, the treatment paradigm for systemic sclerosis has shifted from predominantly symptomatic care toward an organ-targeted, risk-stratified, and increasingly evidence-based model supported by updated international recommendations. The objective of this review was to synthesize modern treatment approaches for systemic sclerosis with emphasis on interstitial lung disease, pulmonary arterial hypertension, vascular digital complications, skin fibrosis, renal crisis, and gastrointestinal involvement. A structured narrative review design was used, drawing primarily on updated EULAR recommendations for systemic sclerosis, ACR and CHEST guidance on screening, monitoring, and treatment of interstitial lung disease in systemic autoimmune rheumatic diseases, the ATS clinical practice guideline for systemic sclerosis-associated interstitial lung disease, ESC/ERS pulmonary hypertension guidance, pivotal randomized clinical trials, and current regulatory labeling for tocilizumab and nintedanib. The analysis shows that modern care is no longer based on a single best drug for all patients; rather, it requires early phenotyping, continuous monitoring, and coordinated multidisciplinary treatment. Mycophenolate has emerged as a central therapy for systemic sclerosis-associated interstitial lung disease, whereas cyclophosphamide, rituximab, tocilizumab, and nintedanib occupy important roles depending on inflammatory activity, fibrotic progression, tolerance, and treatment goals. For vascular disease, calcium channel blockers, phosphodiesterase-5 inhibitors, iloprost, and bosentan remain relevant, while pulmonary arterial hypertension is now approached with early combination therapy in appropriately selected patients. Scleroderma renal crisis still  represents a medical emergency in which immediate angiotensin-converting enzyme inhibition is critical, and gastrointestinal disease requires aggressive supportive and pharmacologic management. High-intensity immunosuppression followed by autologous hematopoietic stem-cell transplantation has an established but highly selective role in early severe diffuse cutaneous disease with poor prognosis. Contemporary management therefore depends on rapid recognition of organ involvement, individualized sequencing of immunomodulatory and antifibrotic therapy, careful safety surveillance, and integration of rheumatology, pulmonology, cardiology, nephrology, gastroenterology, rehabilitation, and specialized nursing care.